The week in pharma: action, reaction and insight – week to November 25, 2022

27 November 2022

By Barbara Obstoj-Cardwell. Editor

Notable news last week including the UK’s GSK on Monday announcing it is withdrawing the US marketing authorization for its multiple myeloma drug Blenrep. The same day, the US Food and Drug Administration (FDA) approved the first one-time hemophilia B treatment, Hemgenix, developed by Dutch firm uniQure and to be marketed in the USA by CSL Behring. Last Wednesday, US biotech Arvinas released data from a Phase III trial of its breast cancer candidate ARV-471. Also of note, BioMarin had some good news, when it revealed that the FDA had done a U-turn on its review of hemophilia A candidate Roctavian, saying it would not after all hold an advisory committee evaluation of the product.

GSK’s “crown jewels” already look tarnished

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK